Actuate Therapeutics Inc (ACTU) Stock Analysis

What Actuate Therapeutics Inc does

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Key metrics

ETFs linked to ACTU

Broad-market and Healthcare sector ETFs an investor holding Actuate Therapeutics Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ACTU fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Actuate Therapeutics Inc?

Actuate Therapeutics Inc trades under the ticker ACTU on NASDAQ.

Which exchange is ACTU listed on?

ACTU is listed on NASDAQ.

What sector does Actuate Therapeutics Inc operate in?

Actuate Therapeutics Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ACTU in a portfolio?

PortView shows ACTU's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.